Astellas Pharma has expanded its US-based global development team with four new senior appointments.
Former Eli Lilly Vice President of Translational Medicine & Pharmacogenomics, Stephen Eck has joined the company as Vice President, Head of Medical Oncology. He brings more than 28 years of pharma experience in the area of oncology research.
Karen Reeves, previous Vice President at Pfizer, has become Vice President, Global Head of Medical Science at Astellas. She has more than 16 years of experience in phase I – IV drug development across multiple therapeutic areas, including neuroscience, oncology, and infectious diseases.
Mark Weinberg has taken the role of Astellas’ Therapeutic Area Head for CNS and Pain, following 12 years’ industry experience, most recently at Lundbeck where he focused on CNS.
Astellas has also appointed Bernhardt Zeiher as Vice President, Therapeutic Area Leader of Inflammation, Immunology and Infectious Diseases. He joins the company from Pfizer, where he was vice president of the inflammation/immunology therapeutic area.
“We are proud to have these outstanding professionals on the Astellas team,” said Dr. Steven Ryder, President of Astellas Pharma Global Development (APGD). “Their shared experience will add tremendous value to the company and will help accelerate APGD’s goal of introducing innovative and valuable new medical treatments.”